耐多药结核描述至少对两种主要一线抗结核药物-异烟肼和利福平具耐药性的结核菌株。
MDR-TB (Multidrug Resistant TB) describes strains of tuberculosis that are resistant to at least the two main first-line TB drugs - isoniazid and rifampicin.
耐多药结核病是耐药结核病的一种特殊形式，由于某一杆菌至少对异烟肼和利福平这两个最强有力的抗结核药品产生耐药而造成。
MDR-TB is a specific form of drug-resistant TB due to a bacillus resistant to at least isoniazid and rifampicin, the two most powerful anti-TB drugs.
耐多药结核病是由对多数有效抗结核病药物（异烟肼和利福平）都具有耐药性的细菌引起的。
MDR-TB is caused by bacteria that are resistant to the most effective anti-TB drugs (isoniazid and rifampicin).
结论：将抗结核药利福平制备成微球制剂，肺部分可提高药物在肺部的分布，静注后无明显不良反应。
CONCLUSION: the lung tissue pulmonary distribution rate of rifampin may be promoted by making rifampin into microsphere dosage form and there were no significant side effects.
方法：采用含卷曲霉素、结核清、氧氟沙星、复合利福平及吡嗪酰胺等抗结核药物方案对耐多药肺结核患者进行治疗。
Methods: The tuberculosis of multi-drug resistance were treated with capreomycin, pasinizide, ofloxacin, rifampin compound and pyrazinamide for one year.
掌握异烟肼、利福平作用机制、临床应用、主要不良反应。 熟悉其它抗结核病药及抗麻风病药的临床选药。
Chapter 45 Antituberculous drugs and Antileprosy drugs Master the mechanisms of action, therapeutic applications and major adverse reactions of isoniazid and rifampin.
掌握异烟肼、利福平作用机制、临床应用、主要不良反应。 熟悉其它抗结核病药及抗麻风病药的临床选药。
Chapter 45 Antituberculous drugs and Antileprosy drugs Master the mechanisms of action, therapeutic applications and major adverse reactions of isoniazid and rifampin.
应用推荐